Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
about
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsNewer therapies for the treatment of metastatic breast cancer: a clinical updateSystemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineFactors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.Treatment-related mortality with everolimus in cancer patients.Breast Cancer 2012 - New AspectsTips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialRole of lapatinib alone or in combination in the treatment of HER2-positive breast cancerBenefit-risk assessment of bevacizumab in the treatment of breast cancer.Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?Primary systemic therapy in HER2-amplified breast cancer: a clinical review.SEOM clinical guidelines for the systemic treatment of early breast cancer 2013.Dermatological toxicity associated with targeted therapies in cancer: optimal management.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
P2860
Q24198118-6069D5BA-72AB-4902-819F-1678A8D0A823Q26865260-83A99C59-D657-4197-9D15-B91A4479117FQ28260063-786B0F37-4F92-424D-AF0C-8C7FAE1811B4Q30313653-6EF40557-A745-4867-BEEB-338CDD92D435Q33699582-E97F3150-D32C-409C-B65E-3274CF798676Q34209663-FCFCDD8E-1023-42E2-9D22-26E1251C2222Q35572763-4DEEDAFE-92D3-4E44-93FC-D8E88035EB49Q35667692-9E8384DE-5685-4763-9891-A91C56E36016Q36212421-70E72A7B-E74C-45AF-9B54-6F2F8C0927CCQ36299086-E535E992-F1D5-4FD3-95DF-498E945B3F89Q37355762-45006B1D-2B97-4941-B38D-54FF512D812AQ37963955-F7D338AC-4F76-4C3F-8FD6-12CD72D2DE49Q37986561-BA2D023B-8837-4F9F-B7FB-028018A3C451Q38048814-0D30EF75-5555-4D21-8EDC-CE3FF0757CA8Q38131743-DD6854A3-8C10-4F12-944F-703DAC56A688Q38239381-86274DDA-C161-4CA7-9BE0-ABD1CB58CDE7Q38682028-7F91785C-FD7B-4288-9D1D-AD66567FCFF7Q46721561-8E2D4684-F1DA-4A70-B785-2CA7121D7E4BQ52641327-41B3F6B1-5CFB-41B4-B3CD-03533E6CA98FQ52886164-51378D8F-654B-4659-B9C6-9271BB341636Q53618240-3A8828DC-5567-47F8-8BFB-CE84F7E08665
P2860
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Integrating bevacizumab, evero ...... ults of the GeparQuinto trial.
@ast
Integrating bevacizumab, evero ...... ults of the GeparQuinto trial.
@en
type
label
Integrating bevacizumab, evero ...... ults of the GeparQuinto trial.
@ast
Integrating bevacizumab, evero ...... ults of the GeparQuinto trial.
@en
prefLabel
Integrating bevacizumab, evero ...... ults of the GeparQuinto trial.
@ast
Integrating bevacizumab, evero ...... ults of the GeparQuinto trial.
@en
P2093
P50
P356
P1433
P1476
Integrating bevacizumab, evero ...... ults of the GeparQuinto trial.
@en
P2093
D Strumberg
G von Minckwitz
German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators
H Eidtmann
J Hilfrich
J-U Blohmer
R Kreienberg
P304
P356
10.1093/ANNONC/MDQ350
P577
2010-07-12T00:00:00Z